ANTHEMNSEAnthem Biosciences Limited· Pharmaceuticals & BiotechnologyMediumNeutral
Announced Mon, 18 Aug, 2025 · 16:16 IST

Anthem Biosciences Limited has informed the Exchange about Transcript

Order pipeline disclosedInvestor Communications View source PDFExplain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.0%Reaction day
₹799.95
prior close
₹798.00
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.9%+1.1% vs market
Pharmaceuticals & Biotechnology peers, median of 155sector · industry level+0.4%+1.6% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.7
10m
+1.9
15m
+1.7
30m
+1.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.0+0.9+1.1+0.4+1.6
Next day
+5.3+1.4+3.9+0.4+4.8
2d
+5.5+1.0+4.5+0.5+5.0
3d
+2.7+0.8+1.9+0.3+2.4
4d
+5.4+0.8+4.7+0.0+5.4
5d
+4.5-0.7+5.2-1.1+5.6
1w
+2.9-2.4+5.3-1.9+4.8
15d
+2.0+1.1+0.9-0.1+2.1
1m
+5.8+3.0+2.8+1.6+4.2
2m
-8.9+3.1-12.0-2.5-6.4
3m
-19.5+5.4-24.9-5.9-13.7
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals & Biotechnology peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anthem Biosciences reported its first quarterly results as a listed company, posting consolidated revenue of INR 540 crore for Q1 FY26, up ~60% year-on-year, driven by strong ramp-up in the CRDMO (Contract Research, Development & Manufacturing) business at INR 452.7 crore and specialty ingredients at INR 87.5 crore. EBITDA stood at INR 214.3 crore with margins of 38% and profit after tax of INR 135.8 crore, with the company sitting on a strong net cash position of INR 784.8 crore. Management confirmed that 54 KL of the planned 155 KL custom synthesis capacity addition was commissioned in Q1, with the balance to be completed this calendar year, and that the late-stage pipeline shifted from 10 Phase 3 products to 8 as two molecules received commercial approval, taking the commercial portfolio from 10 to 12. Management maintained its ~20% long-term revenue growth outlook and said margins are expected to remain steady, with a multi-year Unit 4 expansion underway funded largely from internal cash. The company also indicated active participation in the GLP-1 opportunity and commercial-scale readiness in peptides, ADCs, and RNA/lipid modalities.

Likely market impact

Strong quarter with healthy margins and a net cash balance sheet supports continued capacity-led growth; pipeline additions and entry into GLP-1 provide medium-term optionality, though investors should note management's own caution that Q1 had exceptional commercial product uptake and that quarterly performance may be lumpy.